Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2006 by University Hospital Muenster.
Recruitment status was Recruiting

Sponsor:

Information provided by:

University Hospital Muenster

ClinicalTrials.gov Identifier:

NCT00132223

First received: August 18, 2005

Last updated: April 11, 2006

Last verified: April 2006

History of Changes

Purpose

Angiographies of the supra-aortic vessels by magnetic imaging have become common recently. So it was the purpose of this study to evaluate the imaging potential of different contrast agents.

Three contrast agents for magnetic resonance imaging are compared in angiographies of the supra-aortic arteries in a intraindividual study of 10 patients.

All applications of these contrast agents are performed with a flow of 2 ml/s. One contrast medium is applicated a second time with a reduced flow of 1 ml/s.

The angiographies of the supra-aortic vessels are evaluated by two experienced readers in a consensus reading. The signal/noise- and contrast/noise-ratio of anatomic vessel segments of the carotic and vertebral arteries are measured and compared to each other.

Condition	Intervention	Phase
Headache Epilepsy Dizziness	Drug: Contrast agent	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Single Blind Primary Purpose: Diagnostic
Official Title:	Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging

Resource links provided by NLM:

Genetics Home Reference related topics: pyridoxal 5'-phosphate-dependent epilepsy

MedlinePlus related topics: Diagnostic Imaging Dizziness and Vertigo Epilepsy Headache Noise

U.S. FDA Resources

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:

intensity of vessels, muscle, air

Secondary Outcome Measures:

signal/noise ratio
contrast/nose ratio


Estimated Enrollment:	10
Study Start Date:	April 2005
Estimated Study Completion Date:	December 2005

Eligibility


Ages Eligible for Study:	18 Years to 60 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Headache
Epilepsia
Dizziness

Exclusion Criteria:

Pregnancy
Metal implants (e.g. pacemaker)
Contraindication for contrast agent
Multiple allergies

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00132223

Contacts


Contact: Boris Buerke, MD	00492518345123	buerkeb@uni-muenster.de
Contact: Bernd Tombach, MD	00492518345123	tombach@uni-muenster.de

Locations


Germany
University of Muenster, Dept. of Clinical Radiology	Recruiting
Muenster, Germany, 48129
Contact: Boris Buerke, MD 00492518345123 buerkeb@uni-muenster.de
Contact: Bernd Tombach 00492518345123 tombach@uni-muenster.de
Principal Investigator: Bernd Tombach, MD
Sub-Investigator: Boris Buerke, MD

Sponsors and Collaborators

University Hospital Muenster

Investigators


Study Chair:	Bernd Tombach, MD	University of Muenster, Dept. of Clinical Radiology

More Information


ClinicalTrials.gov Identifier:	NCT00132223 History of Changes
Other Study ID Numbers:	0710/2004-IKR
Study First Received:	August 18, 2005
Last Updated:	April 11, 2006
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Muenster:


magnetic imaging angiography contrast agent	signal/noise ratio contrast/noise ratio vessel

Additional relevant MeSH terms:


Dizziness Vertigo Epilepsy Headache Brain Diseases Central Nervous System Diseases Nervous System Diseases Pain Neurologic Manifestations Signs and Symptoms Sensation Disorders Vestibular Diseases Labyrinth Diseases	Ear Diseases Otorhinolaryngologic Diseases Glucuronyl glucosamine glycan sulfate Anticoagulants Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents Fibrinolytic Agents Fibrin Modulating Agents Hypoglycemic Agents Physiological Effects of Drugs

ClinicalTrials.gov processed this record on September 30, 2016

To Top